Prime study finds individuals enrolled in the program for six months who took GLP-1 drugs for obesity lost an average of 22.5 pounds, and 95% of patients remained on GLP-1 therapy

A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the cost impact of GLP-1 medications, offering critical...

Emerging evidence shows GLP-1 therapies improve health outcomes, but questions remain about their long-term impact on total health care costs

Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

Editor's message Gene therapy= Aims to fix a faulty gene or replace it with a healthy gene to try to cure a disease or help the body become better at fighting disease Maryam Tabatabai, PharmD...

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

Award-winning research from Prime Therapeutics highlighted significant gains in one-year persistence rates for GLP-1 weight-loss therapies among commercially insured adults

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access

Prime Therapeutics experts examine how GLP-1 discontinuation trends shape benefit strategies, patient outcomes and long-term affordability

cover image for Cell & Gene Pipeline Outlook: January 2026 Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-january-2026 Prime Therapeutics’ Cell & Gene...

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

cover image Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-june-2026 Prime Therapeutics’ Cell & Gene Pipeline Outlook is an industry report that...

Live updates from AMCP Annual Meeting

Drug Approvals Monthly Update: March 2024 Traditional New drugs 3/04/2024 clobetasol propionate 0.05% The FDA approved the first clobetasol propionate ophthalmic formulations. The 0.05% suspension...

Cover for 2023 January Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jan?fr=sODMzODc3NDc1ODQ About...

Cover for 2023 April Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_apr?fr=xKAE9_zU1NQ About Prime...

Cover for 2023 July Quarterly Pipeline a view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jul?fr=sMjFiMTc3NDc1ODQ About...

Cover for 2023 October Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_oct?fr=sMTIyZTc3NDc1ODQ About...